The Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2021 report provides a detailed understanding and analysis of how, why and what terms companies enter preclinical stage partnering deals.
These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest preclinical agreements announced in the healthcare sector.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of over 2,400 preclinical stage partnering deals announced since 2014 including financial terms, where available, including links to online deal records of actual preclinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.
In addition, a comprehensive appendix of all preclinical deals since 2014 is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of preclinical stage products and compounds.
Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2021 includes:
Trends in preclinical stage dealmaking in the biopharma industry since 2014
Analysis of preclinical stage deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life preclinical stage deals
Access to over 2,400 preclinical stage deals
The leading preclinical stage deals by value since 2014
Most active preclinical stage dealmakers since 2014
The leading preclinical stage partnering resources
In Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2021, the available contracts are listed by:
Stage of development at signing
Specific therapy target
Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sale sand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Why do companies partner preclinical stage compounds? 2.1. Introduction 2.2. The role of preclinical stage partnering 2.2.1. In-licensing at preclinical stage 2.2.2. Out-licensing at preclinical stage 2.3. Difference between discovery, preclinical and clinical stage deals 2.4. Reasons for entering into preclinical stage partnering deals 2.4.1. Licensors reasons for entering preclinical stage deals 2.4.2. Licensees reasons for entering preclinical stage deals 2.5. The future of preclinical stage partnering deals
Chapter 3 - Preclinical stage deal strategies and structure 3.1. Introduction 3.2. At what stage do companies partner? 3.2.1. Partnering early in pharmaceutical / biotech 126.96.36.199. Discovery and preclinical stage partnering case studies 188.8.131.52.a. Case study: LEO Pharma - 4SC 184.108.40.206.b. Case study: Heptares Therapeutics - Cubist 220.127.116.11.c. Case study: Incyte - Agenus Bio 18.104.22.168.d. Case study: Janssen Pharmaceutical - Evotec 3.2.2. Partnering later in pharmaceutical/biotech 22.214.171.124. Clinical stage partnering case studies 126.96.36.199.a. Case study: Servier - GeNeuro 188.8.131.52.b. Case study: Teva - Xenon Pharmaceuticals 184.108.40.206.c. Case study: AstraZeneca - Ardelyx 220.127.116.11.d. Case study: Baxter - Onconova Therapeutics 3.3. Early and later stage partnering - a risk/cost comparison 3.4. What do companies spend on preclinical stage partnering? 3.5. Pure versus multi-component partnering deals 3.6. Pure licensing agreement structure 3.6.1. Example pure preclinical stage licensing agreements 3.6.1.a. Case study : Merck and Co. - Tesaro 3.6.1.b. Case study : Marina Biotech - Mirna Therapeutics 3.7. Multicomponent preclinical stage partnering agreements 3.7.1. Example multicomponent preclinical stage clauses 3.7.1.a. Case study: Eleven Biotherapeutics - ThromboGenics 3.7.1.b. Case study: Pfizer - InSite Vision
Chapter 5 - Trends in preclinical stage deal making 5.1. Introduction 5.2. Preclinical stage partnering over the years 5.2.1. Attributes of preclinical deals 5.3. Preclinical stage partnering by deal type 5.4. Preclinical stage partnering by disease type 5.5. Partnering by preclinical stage technology type 5.6. Preclinical stage partnering by most active company since 2014